Vaxcyte (PCVX) Research & Development (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Research & Development data on file, last reported at $312.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $312.8 million, up 111.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $959.0 million (up 80.87% YoY), and the FY2025 annual result was $794.3 million, up 66.65% from the prior year.
• Research & Development climbed to $312.8 million in Q1 2026 per PCVX's latest filing, from $242.1 million in the prior quarter.
• Over five years, Research & Development peaked at $312.8 million in Q1 2026 and troughed at $31.7 million in Q1 2022.
• A 5-year average of $122.7 million and a median of $104.2 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development surged 133.4% in 2022, then advanced 20.03% in 2024.
• A 5-year view of Research & Development shows it stood at $51.6 million in 2022, then soared by 101.74% to $104.2 million in 2023, then grew by 28.29% to $133.6 million in 2024, then soared by 81.16% to $242.1 million in 2025, then increased by 29.22% to $312.8 million in 2026.
• Business Quant data shows PCVX's Research & Development at $312.8 million in Q1 2026, $242.1 million in Q4 2025, and $209.9 million in Q3 2025.